China Pharma Holdings (CPHI) Change in Receivables (2010 - 2026)

China Pharma Holdings (CPHI) has reported Change in Receivables for 17 consecutive years, with $151378.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Receivables rose 636.06% year-over-year to $151378.0; the trailing twelve-month figure through Jun 2026 stood at -$13.2 million (down 2439.31% YoY), and the FY2025 full-year result was -$13.2 million, down 6780.77% from the prior year.
• Change in Receivables grew to $151378.0 in Q2 2026 per CPHI's latest filing, from $14019.0 in the prior quarter.
• Across five years, Change in Receivables topped out at $434306.0 in Q1 2023 and bottomed at -$13.5 million in Q4 2025.
• Historically, Change in Receivables has averaged -$652060.8 across 5 years, with a median of $113758.0 in 2022.
• The sharpest annual moves came in 2025 and 2026: Change in Receivables slumped 6444.99% in 2025, then jumped 636.06% in 2026.
• Over 5 years, Change in Receivables stood at $107286.0 in 2022, then soared by 239.52% to $364258.0 in 2023, then sank by 41.54% to $212942.0 in 2024, then plunged by 6444.99% to -$13.5 million in 2025, then soared by 101.12% to $151378.0 in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $151378.0, $14019.0, and -$13.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.